Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,511.00-0.52%ETH$2,696.35-0.71%GOLD$4,192.90+0.14%OIL$89.86+0.47%
Smart Investors Daily
SID Premium
OL

NASDAQ · OLMA

Olema Pharmaceuticals, Inc.

Healthcare · Biotechnology

$8.25

Down-$0.33 (-4.00%)

Updated Oct 6, 2026, 11:27 PM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.17B
P/E ratio
-18.05
Dividend yield
0.00%
52-week range
$6.65 – $36.26
Volume
1.01M
Avg. volume
3.41M

Price performance · OLMA

OLMA price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

OLMA closed at $8.25 after 20 trading sessions, down 24.90% for the selected period.

Last close
$8.25
Period change
-24.90%
Period low
$8.23
Period high
$10.99
Daily close
View OHLC price history
OLMA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$8.28$8.30$7.85$8.251.01M
Oct 2, 2026$8.39$8.52$8.10$8.2251.07M
Oct 1, 2026$8.58$8.66$8.19$8.271.01M
Sep 30, 2026$8.59$8.86$8.42$8.641.54M
Sep 29, 2026$8.60$8.73$8.46$8.541.08M
Sep 28, 2026$8.71$8.85$8.40$8.61979.23K
Sep 25, 2026$9.04$9.04$8.57$8.751.38M
Sep 24, 2026$8.79$9.27$8.59$9.041.49M
Sep 23, 2026$9.64$9.64$8.70$8.831.64M
Sep 22, 2026$9.66$9.815$9.56$9.641.49M
Sep 21, 2026$9.95$10.13$9.61$9.631.07M
Sep 18, 2026$9.88$9.93$9.75$9.823.06M
Sep 17, 2026$9.89$10.35$9.73$9.901.09M
Sep 16, 2026$9.86$9.93$9.44$9.731.25M
Sep 15, 2026$10.29$10.34$9.65$9.781.73M
Sep 14, 2026$9.99$10.37$9.79$10.291.82M
Sep 11, 2026$10.79$10.86$10.18$10.221.01M
Sep 10, 2026$10.19$10.98$10.11$10.691.12M
Sep 9, 2026$11.13$11.18$10.35$10.36863.84K
Sep 8, 2026$10.61$11.055$10.46$10.985736.72K

Latest OLMA news

The latest Smart Investors Daily articles mentioning OLMA.

Stock researchCompany · Overview

OLMA research

Overview

Company profile and research snapshot.

Company profile

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$42.80
Implied upside
—
Analysts
—
OLMA recent ratings
DateFirmRatingTarget
Sep 14, 2026StifelBuy—
Aug 13, 2026JP MorganOverweight—
Aug 11, 2026CitigroupBuy—
Aug 11, 2026HC Wainwright & Co.Buy—
May 13, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 2, 2026

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 235,950 shares of the Company's common stock, effective as of October 1, 2026. These awards were approved by the Compe

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By